MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 577475 | Name: Mitoxantrone diacetate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Mitoxantrone diacetate is an anthraquinone that intercalates in DNA and inhibits topoisomerase II.

Chemical Structure

Mitoxantrone diacetate
Mitoxantrone diacetate
CAS#70711-41-0 (diacetate)

Theoretical Analysis

MedKoo Cat#: 577475

Name: Mitoxantrone diacetate

CAS#: 70711-41-0 (diacetate)

Chemical Formula: C26H36N4O10

Exact Mass: 564.2431

Molecular Weight: 564.59

Elemental Analysis: C, 55.31; H, 6.43; N, 9.92; O, 28.34

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
70476-82-3 (HCl) 65271-80-9 (free base) 70711-41-0 (diacetate)
Synonym
Dhaq diacetate; Mitoxantrone diacetate
IUPAC/Chemical Name
2,2'-((5,8-dihydroxy-9,10-dioxo-9,10-dihydroanthracene-1,4-diyl)bis(azanediyl))bis(N-(2-hydroxyethyl)ethan-1-aminium) acetate
InChi Key
ZWCKUVMZBKQQRG-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H28N4O6.2C2H4O2/c27-11-9-23-5-7-25-13-1-2-14(26-8-6-24-10-12-28)18-17(13)21(31)19-15(29)3-4-16(30)20(19)22(18)32;2*1-2(3)4/h1-4,23-30H,5-12H2;2*1H3,(H,3,4)
SMILES Code
CC(=O)[O-].CC(=O)[O-].OCC[NH2+]CCNc1ccc(NCC[NH2+]CCO)c2C(=O)c3c(O)ccc(O)c3C(=O)c12
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 564.59 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Kapoor T, Mehan S. Neuroprotective methodologies in treatment of Multiple Sclerosis: Current status of Clinical and Pre-clinical findings. Curr Drug Discov Technol. 2020 Feb 6. doi: 10.2174/1570163817666200207100903. [Epub ahead of print] PubMed PMID: 32031075. 2: Wei H, Wang Y, Gale RP, Lin D, Zhou C, Liu B, Qiu S, Gu R, Li Y, Zhao X, Wei S, Gong B, Liu K, Gong X, Liu Y, Zhang G, Song Z, Wang Y, Li W, Mi Y, Wang J. Randomized trial of intermediate-dose cytarabine in induction and consolidation therapy in adults with acute myeloid leukaemia. Clin Cancer Res. 2020 Feb 6. pii: clincanres.3433.2019. doi: 10.1158/1078-0432.CCR-19-3433. [Epub ahead of print] PubMed PMID: 32029439. 3: Zinzani PL, Derenzini E, Pellegrini C, Rigacci L, Fabbri A, Gandolfi L, Argnani L, Casadei B, Pulsoni A, Gobbi M, Perotti A, Zaccaria A, Voso MT, Cabras MG, De Renzo A. Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma). Ann Oncol. 2012 Mar;23(3):805-807. doi: 10.1093/annonc/mdr633. Epub 2019 Dec 4. PubMed PMID: 32018684. 4: Scheckel CJ, Meyer M, Betcher JA, Al-Kali A, Foran J, Palmer J. Efficacy of mitoxantrone-based salvage therapies in relapsed or refractory acute myeloid leukemia in the Mayo Clinic Cancer Center: Analysis of survival after 'CLAG-M' vs. 'MEC'. Leuk Res. 2020 Jan 28;90:106300. doi: 10.1016/j.leukres.2020.106300. [Epub ahead of print] PubMed PMID: 32018118. 5: Djeni TN, Kouame KH, Ake FDM, Amoikon LST, Dje MK, Jeyaram K. Microbial Diversity and Metabolite Profiles of Palm Wine Produced From Three Different Palm Tree Species in Côte d'Ivoire. Sci Rep. 2020 Feb 3;10(1):1715. doi: 10.1038/s41598-020-58587-2. PubMed PMID: 32015447. 6: Lin KN, Jiang YL, Zhang SG, Huang SY, Li H. Grape seed proanthocyanidin extract reverses multidrug resistance in HL-60/ADR cells via inhibition of the PI3K/Akt signaling pathway. Biomed Pharmacother. 2020 Jan 30;125:109885. doi: 10.1016/j.biopha.2020.109885. [Epub ahead of print] PubMed PMID: 32007917. 7: Baltes F, Pfeifer V, Silbermann K, Caspers J, Wantoch von Rekowski K, Schlesinger M, Bendas G. β(1)-Integrin binding to collagen type 1 transmits breast cancer cells into chemoresistance by activating ABC efflux transporters. Biochim Biophys Acta Mol Cell Res. 2020 Jan 25;1867(5):118663. doi: 10.1016/j.bbamcr.2020.118663. [Epub ahead of print] PubMed PMID: 31987794. 8: Liu Y, Liao Y, Li P, Li ZT, Ma D. Cross-Linked Pillar[6]arene Nanosponges Fabricated by the Use of a Supra-Amphiphilic Template: Cargo Encapsulation and Overcoming Multidrug Resistance. ACS Appl Mater Interfaces. 2020 Feb 5. doi: 10.1021/acsami.9b22066. [Epub ahead of print] PubMed PMID: 31985197. 9: Burke MJ, Kostadinov R, Sposto R, Gore L, Kelley SM, Rabik C, Trepel JB, Lee MJ, Yuno A, Lee S, Bhojwani D, Jeha S, Chang BH, Sulis ML, Hermiston ML, Gaynon P, Huynh V, Verma A, Gardner R, Heym KM, Dennis RM, Ziegler DS, Laetsch TW, Oesterheld JE, Dubois SG, Pollard JA, Glade-Bender J, Cooper TM, Kaplan JA, Farooqi MS, Yoo B, Guest E, Wayne AS, Brown PA. Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study. Clin Cancer Res. 2020 Jan 22. pii: clincanres.1251.2019. doi: 10.1158/1078-0432.CCR-19-1251. [Epub ahead of print] PubMed PMID: 31969338. 10: Wu ZX, Yang Y, Teng QX, Wang JQ, Lei ZN, Wang JQ, Lusvarghi S, Ambudkar SV, Yang DH, Chen ZS. Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance. Cancers (Basel). 2020 Jan 12;12(1). pii: E186. doi: 10.3390/cancers12010186. PubMed PMID: 31940916. 11: Wawrzyniak S, Rzepiński Ł. Is there a new place for mitoxantrone in the treatment of multiple sclerosis? Neurol Neurochir Pol. 2020 Jan 10. doi: 10.5603/PJNNS.a2019.0069. [Epub ahead of print] PubMed PMID: 31922582. 12: Najafian J, Nasri A, Etemadifar M, Salehzadeh F. Late Cardiotoxicity in MS Patients Treated with Mitoxantrone. Int J Prev Med. 2019 Dec 10;10:211. doi: 10.4103/ijpvm.IJPVM_477_17. eCollection 2019. PubMed PMID: 31921403; PubMed Central PMCID: PMC6941302. 13: Thiele Née Schrewe L, Guse K, Tietz S, Remlinger J, Demir S, Pedreiturria X, Hoepner R, Salmen A, Pistor M, Turner T, Engelhardt B, Hermann DM, Lühder F, Wiese S, Chan A. Functional relevance of the multi-drug transporter abcg2 on teriflunomide therapy in an animal model of multiple sclerosis. J Neuroinflammation. 2020 Jan 8;17(1):9. doi: 10.1186/s12974-019-1677-z. PubMed PMID: 31915017; PubMed Central PMCID: PMC6951012. 14: Chang A. A case of mitoxantrone extravasation. J Oncol Pharm Pract. 2020 Jan 6:1078155219893736. doi: 10.1177/1078155219893736. [Epub ahead of print] PubMed PMID: 31902285. 15: Wu J, Lin Z, Weng X, Owens G, Chen Z. Removal mechanism of mitoxantrone by a green synthesized hybrid reduced graphene oxide @ iron nanoparticles. Chemosphere. 2019 Dec 19;246:125700. doi: 10.1016/j.chemosphere.2019.125700. [Epub ahead of print] PubMed PMID: 31884233. 16: Cornet C, Dyballa S, Terriente J, Di Giacomo V. ZeOncoTest: Refining and Automating the Zebrafish Xenograft Model for Drug Discovery in Cancer. Pharmaceuticals (Basel). 2019 Dec 24;13(1). pii: E1. doi: 10.3390/ph13010001. PubMed PMID: 31878274. 17: Pumuye PP, Evison BJ, Konda SK, Collins JG, Kelso C, Medan J, Sleebs BE, Watson K, Phillips DR, Cutts SM. Formaldehyde-activated WEHI-150 induces DNA interstrand crosslinks with unique structural features. Bioorg Med Chem. 2020 Feb 1;28(3):115260. doi: 10.1016/j.bmc.2019.115260. Epub 2019 Dec 14. PubMed PMID: 31870833. 18: Lozano E, Asensio M, Perez-Silva L, Banales JM, Briz O, Marin JJG. MRP3-mediated chemoresistance in cholangiocarcinoma: Target for chemosensitization through restoring SOX17 expression. Hepatology. 2019 Dec 20. doi: 10.1002/hep.31088. [Epub ahead of print] PubMed PMID: 31863486. 19: Rossi A, Pakhomova ON, Mollica PA, Casciola M, Mangalanathan U, Pakhomov AG, Muratori C. Nanosecond Pulsed Electric Fields Induce Endoplasmic Reticulum Stress Accompanied by Immunogenic Cell Death in Murine Models of Lymphoma and Colorectal Cancer. Cancers (Basel). 2019 Dec 17;11(12). pii: E2034. doi: 10.3390/cancers11122034. PubMed PMID: 31861079; PubMed Central PMCID: PMC6966635. 20: Narayan R, Blonquist TM, Emadi A, Hasserjian RP, Burke M, Lescinskas C, Neuberg DS, Brunner AM, Hobbs G, Hock H, McAfee SL, Chen YB, Attar E, Graubert TA, Bertoli C, Moran JA, Bergeron MK, Foster JE, Ramos AY, Som TT, Vartanian MK, Story JL, McGregor K, Macrae M, Behnan T, Wey MC, Rae J, Preffer FI, Lesho P, Duong VH, Mann ML, Ballen KK, Connolly C, Amrein PC, Fathi AT. A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia. Cancer. 2019 Dec 20. doi: 10.1002/cncr.32657. [Epub ahead of print] PubMed PMID: 31860140.

View History

Lysine aspartate

Lysine aspartate